Adlai Nortye Biopharma Co., Ltd., a biopharmaceutical company, has entered into a global licensing agreement with Eisai Co., Ltd., a global pharmaceutical company with a focus on serving patients with unmet medical needs.
Under the terms of the agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture, and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China.
E7046 is an investigational, oral EP4 antagonist (potentially first in class) with high activity and high selectivity. Based on preliminary results, it is well tolerated in patients with solid tumors. Phase 1b combination studies with radiotherapy and chemoradiotherapy are in progress.
“With its proposed mechanism of action and impressive preclinical results, we believe that E7046 will become a key component in furthering development of our oncology pipeline,” said Dr. Ruirong Yuan, CMO and president of Adlai Nortye. “In preclinical studies, E7046 combined with radiotherapy, chemoradiotherapy and with immune checkpoint inhibitors demonstrated antitumor activity in different malignancies, including colon rectal cancer, lung cancer and some PD-1 resistant tumor models. We believe that E7046 has great potential for future clinical application in cancer treatment.”
(Source: Adlai Nortye Biopharma Co., Ltd.)
Filed Under: Drug Discovery
